Stock A311690 CJ BIOSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials CJ Bioscience, Inc.

Equities

A311690

KR7311690002

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
14,790 KRW +3.14% Intraday chart for CJ Bioscience, Inc. +7.10% -8.36%
2023 CJ Bioscience, Inc. announced that it has received KRW 24.033 billion in funding from CJ Cheiljedang Corporation CI
2023 CJ Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 143,216 199,288 286,048 170,481 147,076
Enterprise Value (EV) 1 112,869 195,779 229,858 150,124 91,514
P/E ratio -28.5 x -22.6 x -10.7 x -4.88 x -4.99 x
Yield - - - - -
Capitalization / Revenue 29.9 x 37.5 x 65.6 x 41.8 x 26.4 x
EV / Revenue 23.6 x 36.9 x 52.7 x 36.8 x 16.4 x
EV / EBITDA -29.8 x -26.2 x -26.9 x -5.12 x -3.4 x
EV / FCF -66.3 x -11.1 x -34.3 x -8.7 x -2.84 x
FCF Yield -1.51% -8.97% -2.92% -11.5% -35.2%
Price to Book 4.64 x 5.78 x 3.26 x 3.43 x 2.06 x
Nbr of stocks (in thousands) 3,809 3,892 5,874 5,879 9,113
Reference price 2 37,600 51,200 48,700 29,000 16,140
Announcement Date 3/13/20 3/19/21 3/21/22 3/20/23 3/19/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 4,783 5,312 4,363 4,075 5,575
EBITDA 1 -3,788 -7,462 -8,546 -29,333 -26,911
EBIT 1 -4,519 -8,513 -10,108 -33,233 -32,057
Operating Margin -94.47% -160.28% -231.68% -815.61% -575%
Earnings before Tax (EBT) 1 -4,346 -8,763 -19,272 -34,913 -22,913
Net income 1 -4,346 -8,763 -19,272 -34,913 -22,913
Net margin -90.85% -164.97% -441.72% -856.84% -410.99%
EPS 2 -1,317 -2,270 -4,533 -5,940 -3,235
Free Cash Flow 1 -1,702 -17,565 -6,708 -17,249 -32,209
FCF margin -35.58% -330.69% -153.75% -423.33% -577.74%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/13/20 3/19/21 3/21/22 3/20/23 3/19/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 30,348 3,509 56,190 20,357 55,562
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 -1,702 -17,565 -6,708 -17,249 -32,209
ROE (net income / shareholders' equity) -20.9% -26.8% -31.5% -50.8% -37.8%
ROA (Net income/ Total Assets) -12.1% -9.94% -6.66% -20% -22%
Assets 1 35,833 88,193 289,379 174,599 104,366
Book Value Per Share 2 8,101 8,859 14,957 8,447 7,830
Cash Flow per Share 2 1,406 3,406 10,566 8,390 7,019
Capex 1 427 12,018 953 4,145 4,924
Capex / Sales 8.93% 226.27% 21.83% 101.72% 88.32%
Announcement Date 3/13/20 3/19/21 3/21/22 3/20/23 3/19/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CJ BIOSCIENCE, INC. Stock CJ Bioscience, Inc.
-8.36% 97.38M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.19B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 10.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-18.08% 9.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A311690 Stock
  4. Financials CJ Bioscience, Inc.